Alternative Splicing in the Differentiation of Human Embryonic Stem Cells into Cardiac Precursors

Nathan Salomonis¹,², Brandon Nelson³, Karen Vranizan⁴, Alexander R. Pico⁵, Kristina Hanspers¹, Allan Kuchinsky⁵, Linda Ta¹, Mark Mercola³, Bruce R. Conklin¹,²

¹ Gladstone Institute of Cardiovascular Disease, San Francisco, California, United States of America, ² Pharmaceutical Sciences and Pharmacogenomics Graduate Program, University of California, San Francisco, San Francisco, California, United States of America, ³ Burnham Institute for Medical Research, La Jolla, California, United States of America, ⁴ Functional Genomics Laboratory, University of California, Berkeley, Berkeley, California, United States of America, ⁵ Agilent Technologies, Santa Clara, California, United States of America

Abstract

The role of alternative splicing in self-renewal, pluripotency and tissue lineage specification of human embryonic stem cells (hESCs) is largely unknown. To better define these regulatory cues, we modified the H9 hESC line to allow selection of pluripotent hESCs by neomycin resistance and cardiac progenitors by puromycin resistance. Exon-level microarray expression data from undifferentiated hESCs and cardiac and neural precursors were used to identify splice isoforms with cardiac-restricted or common cardiac/neural differentiation expression patterns. Splice events for these groups corresponded to the pathways of cytoskeletal remodeling, RNA splicing, muscle specification, and cell cycle checkpoint control as well as genes with serine/threonine kinase and helicase activity. Using a new program named AltAnalyze (http://www.AltAnalyze.org), we identified novel changes in protein domain and microRNA binding site architecture that were predicted to affect protein function and expression. These included an enrichment of splice isoforms that oppose cell-cycle arrest in hESCs and that promote calcium signaling and cardiac development in cardiac precursors. By combining genome-wide predictions of alternative splicing with new functional annotations, our data suggest potential mechanisms that may influence lineage commitment and hESC maintenance at the level of specific splice isoforms and microRNA regulation.

Introduction

The differentiation of embryonic stem cells (ESCs) in vitro is a powerful system for identifying developmental cues required for lineage commitment. Like their in vivo counterparts, the cells of the inner cell mass of the blastocyst, ESCs can self-renew and differentiate into all three adult germ layers. Maintenance of pluripotency and self-renewal depends on the expression of core transcription factors, including Oct4, Sox2, and Nanog. Whole-genome expression [1], microRNA (miRNA) [2], and epigenetic analyses [3,4] of ESC differentiation have identified additional factors that interact with these core transcription factors to regulate pluripotency. However, the mechanisms that regulate ESC maintenance upstream and downstream of these core regulatory components and the steps required for proper cell fate commitment are poorly understood, largely because of the difficulty of obtaining pure populations of fully differentiated cells and the lack of detailed transcript expression profiles that allow the analysis of transcription and alternative splicing (AS).

Up to 80% of all human genes undergo AS to produce multiple mRNA transcripts that differ in their inclusion of exons and introns [5]. AS often results in unique proteins with biologically distinct compositions and functions [6]. AS can alter domain composition and cellular localization, which can confer distinct signaling properties on the resulting protein. In untranslated mRNA regions, AS can affect RNA stability and localization [6]. Disruption of AS of a single gene can have profound effects on cellular development, ranging from improper neonatal cardiac adaptation [7] to sex-determination [8] and synapto genesis [9].

Since ESCs can differentiate into all cell lineages, characterizing isoform expression along specific lineage paths requires efficient methods to obtain pure cell populations. To this end, hESCs have been differentiated into neural progenitors (NPs), isolated with an effective neural differentiation protocol, and profiled with whole-genome exon-arrays [10]. This technology can measure the expression of distinct RNA regions and thus identify more complex modes of gene regulation. This analysis revealed AS of serine/threonine kinases and helicases, suggesting that coordinated programs in hESCs direct both cell-type-specific and general differentiation programs. Comparative genome sequence analysis within the vicinity of these AS events revealed putative cis-regulatory sequences that may regulate AS in the differentiation to NPs [10].

While these methods were an important step toward delineating the role of AS in differentiation, profiling of other progenitor cell types and comparisons between cell types is required to identify
Isolation of hESCs and CPs

Materials and Methods

The reprogramming of pluripotent stem cells from adult cells is a crucial step toward producing patient-specific cells for transplant therapy. Critical to this goal is the ability to reproducibly drive the differentiation of these cells to specific fates, such as cardiac and neural cells. While gene expression is important in tissue-specific differentiation, the impact of alternative splicing on the biology of differentiating cells has not been fully realized. To identify specific splicing events that may determine cell-type-specific differentiation, we compared splicing profiles of human embryonic stem cells (hESCs) and derived cardiac and neural precursors using Affymetrix exon tiling arrays. Segregation of splicing profiles into cardiac-restricted and common cardiac/neural differentiation pattern groups revealed unique groups of genes with clear implications for the biology of cardiomyocyte function and the maintenance of pluripotent ESCs. Alternative splicing of many of these genes, notably regulators of cell death and proliferation, were often predicted to impact protein domain or microRNA binding site inclusion, suggesting that the function or expression of these proteins is altered during differentiation. These results provide further evidence that alternative splicing is important in shaping the functional repertoire of ESCs and differentiated cells.

and understand common processes in differentiation and processes that are specific to different paths of differentiation. Determining the consequences of AS on a genome-wide basis will require tools to predict the effects of AS on protein sequence, domain inclusion, and protein expression.

In this study, we sought to identify AS during differentiation into different progenitor populations by exon-level genome profiling of homogenous populations of undifferentiated hESCs and derived cardiac progenitors (CPs) using a new selectable marker strategy. By comparing CP differentiation to a reported dataset of neural differentiation [10], we identified AS events found only in the differentiation to CPs or the differentiation to both CPs and NPs (common). AS events with common CP-NP or CP-specific patterns produced profound changes in predicted protein domain/motif composition that could affect protein function and expression. Many AS events modified the predicted microRNA binding site composition of transcripts, suggesting that AS may indirectly modulate protein expression.

Materials and Methods

Isolation of hESCs and CPs

The genetically engineered hESC lines and electrophysiology of derived CPs have been described in detail in [11]. In brief, H9 ESCs were transduced with a lentiviral preparation that encoded a neomycin-resistance gene controlled by the REX-1 promoter and a puromycin-resistance gene controlled by the REX-1 promoter. Stable clonal lines were created by neomycin selection of a homogenous population of undifferentiated hESCs. Embryoid bodies were formed in suspension culture for 6 days from hESCs and transferred to gelatin-coated plates. On day 13 of differentiation, embryoid bodies were treated with puromycin for 36 h to isolate CPs. Total RNA from biological triplicates of neomycin-resistant line 1,0 ST GeneChip arrays as described [10]. As starting material, ~1 μg of total RNA was purified with the RiboMinus human transcriptome isolation kit (Invitrogen), cDNA was frag-

Additional Microarray Data

Human exon array CEL files for the Cythera NP differentiation datasets (Cy-ESCs and Cy-NPs), HUES6 ESCs, HUES6 NPs, and fetal human central nervous system stem cells were provided by the Gage laboratory (http://www.snl.salk.edu/~geneyeo/stuff/papers/supplementary/ES-NP) [10]. Exon array data for 11 adult human tissues (testes, spleen, heart, thyroid, muscle, breast, prostate, liver, kidney, pancreas, cerebellum), were downloaded from the Affymetrix website [13].

Gene Expression Analysis

The methods and program components of AltAnalyze are described in detail in Text S1. For this analysis, AltAnalyze databases (stored as tab-delimited text files) were constructed with build 18 of the UCSC Genome Database [15] and Affymetrix annotation files. For all probe sets, expression values and detection above background (DABG) p values were calculated from AltAnalyze using the Robust Multichip Average algorithm [16] by interfacing with Affymetrix Power Tools (APT) [17].

Alternative Exon Analysis with AltAnalyze

To identify alternative exons, AltAnalyze was run with default parameters. This analysis consists of (A) selecting microarrays for expression summarization with RMA, (B) defining biological groups for each array and pairs of groups for alternative exon analysis (e.g., ESCs and CPs), (C) downloading/loading appropriate library and annotation files for the microarray, (D) defining thresholds for probe set filtering, (E) defining thresholds for alternative exon analysis statistics (splicing-index and MIDAS [18]), (F) determining methods used to identify predicted domains/motifs and microRNA binding sites, (G) running the analysis, and (H) exporting result files (Text S1). We performed two different sets of array normalizations. The first included all aforementioned cell lines and tissues, and the second included only cell lines. The combined cell line and tissue normalization was only used for combined gene expression comparison analyses (Figure 1) and comparison of tissue and cell line splicing patterns. The cell-line-specific normalization was used for all remaining downstream CP and NP alternative exon analyses.
After RMA expression values and gene expression statistics (e.g., hESC and CP group gene expression averages, fold changes, and t test p values) are exported, AltAnalyze filters probe sets to identify those that align to a single Ensembl gene and that match user-defined expression and DABG p value thresholds [Text S1]. Only probe sets with a DABG p ≤ 0.05 and a non-log expression value > 70 [19] are retained for further analysis of all hESC–progenitor pair-wise comparisons. Using the splicing index (SI) method [19,20], AltAnalyze calculates the likelihood and extent of AS for all Ensembl genes with one or more constitutive probe sets. Two probability estimates for alternative exon regulation are calculated with a one-way analysis of variance model, MiDAS [19], by interfacing with APT (version 1.4.0) and SI, by performing a t test of the normalized exon expression values (exon probe set expression divided by constitutive expression) for the control and experimental sample groups.

The primary filters for identifying alternative exons were a conservative SI fold change > 1 (equivalent to a 2-fold difference in expression relative to constitutive expression levels), an SI t test p value < 0.05, a MiDAS p < 0.05, and constitutive gene-expression fold change < 3 (absolute). Genes with a constitutive fold change > 3 were excluded to remove potential false-positive alternative exons that arise when only constitutive probe set variance is observed. For this analysis, we considered only AltAnalyze “core” probe sets and probe sets overlapping with any mRNA contained within the AltAnalyze mRNA database (Ensembl or UCSC Genome Database).

To visualize alternative exons in the context of genes, we wrote a prototype plugin, currently in development, for the network visualization software Cytoscape [21]. This plugin, Subgene-Viewer, allows colors indicating inclusion or exclusion of exons to be mapped onto exon and splicing structures that can be selectively viewed from protein interaction networks or pathways.

**Figure 1. Comparison of hESC differentiation and adult tissue array profiles.** Human Affymetrix exon array data were compared for REX+ hESCs and derived CPs; Cythera, HUES6 hESCs and derived NPs; fetal human central nervous system stem cells (hCNS-scnsc); and 11 adult tissues, processed by RMA together. (A) Relative changes in gene expression (log2 fold, relative to the global expression mean) for all samples were clustered by array (rather than genes) for any Ensembl gene with a relative change in gene expression > 2. Biological triplicates are indicated for each tissue or cell line. (B) Gene expression profiles for this combined dataset and for specific markers of CP-specification (columns 1 and 2) and for pluripotency (column 3). doi:10.1371/journal.pcbi.1000553.g001
of an aligning and nonaligning protein (competitive isoforms) for all probe sets (Figure 2B), corresponding protein sequences, relative comparison information for the two competitive alternative protein isoforms (e.g., alternative-N-terminal, alternative-C-terminal sequence) (Figure 2A), protein domains/motif sequences found in one protein but not the other (Figure 2C), and domains/motifs whose genomic position overlaps with any probe set (Figure 2D). In short, competitive protein isoforms are selected by identifying exons from Ensembl or the UCSC Genome Database that overlap with a probe set based on genomic position, identifying mRNA competitive transcripts that contain or do not contain that exon, comparing the exon structure of all possible competitive transcripts and identifying a single competitive transcript pair that contains the fewest combined distinct exons (exons unique to either transcript) and the most exons in common to both. Corresponding proteins for selected competitive isoforms are identified from Ensembl and NCBI’s web services [22] or are derived by in silico translation. Protein domain and motif sequences are obtained directly from UniProt’s [23] sequence annotation features or from InterPro [24] sequence annotations (alignment e-value <1) for every Ensembl protein. AltAnalyze reports any InterPro sequences with a description field or any UniProt sequence annotation feature that is not of the type CHAIN, CONFLICT, VARIANT, VARSPPLIC, or VAR_SEQ. The competitive protein isoform analysis only considers the alternative exon of interest and does not attempt to combine information from other potential alternative exons. Only InterPro genomic start and end positions are extracted to determine genomic coordinate overlap with probe sets.

In addition to these protein annotations, putative miRNA binding sites from PicTar [25], miranda [26] and TargetScan (http://www.targetscan.org) within probe set consensus sequences are stored in a database for use by AltAnalyze. Protein and miRNA binding site annotations for all alternatively regulated probe sets (alternative exons) are reported in the AltAnalyze results files and are assessed for over-representation. Over-representation is assessed by calculating an over-representation z score, a permutation based p value (derived by re-running the z score analysis 2000 times with random probe set inputs) and a Benjamini-Hochberg [27] adjusted p value of the permutation p to take account for multiple hypothesis correction (Text S1). For all domain/motif and miRNA over-representation analyses, only elements (domain, motif, or miRNA binding site) with a z score >2, Benjamini-Hochberg p<0.05 and three or more genes associated with the element are reported. To test for differences between the number of miRNA binding sites up- and downregulated in hESCs versus CPs, the number of genes with alternative exons up- and downregulated and the number of genes with these patterns of expression and predicted miRNA binding sites are evaluated with a $\chi^2$ test.

Analysis of Variance

To segregate transcriptionally regulated genes and AS events into CP-specific and common CP-NP differentiation patterns, we used a two-way ANOVA strategy in which the LIMMA package in Bioconductor [28] was used to compare day 40 CP arrays with NP arrays along with their respective pluripotent hESC controls. The Cythera hESC line dataset was used to examine NP

![Figure 2. Assigning AltAnalyze mRNA and protein annotations.](image)

Theoretical transcripts with distinct exon compositions are shown. (A) Distinct alternative (Alt.) exon annotations for five mRNA transcripts, where the filled boxes are sequences retained in the processed mRNA transcript. Black filled boxes are exons common to all isoforms (constitutive). AltAnalyze considers all alternative exon annotations as AS except for alternative-N-terminal exons (expressed through alternative promoter selection). (B) All pairs of mRNA transcripts that do or do not align to an exon array probe set are compared to identify a single pair of competitive isoforms that minimally differ in exon composition. Curved arrows indicate all possible competitive transcript comparisons. The top selected competitive isoforms (dashed box) have the fewest exon differences and have the most exons in common. AltAnalyze selects this transcript pair for analysis of downstream protein domain/motif composition, after corresponding protein sequences are selected. (C) Protein domains and motifs differing between competitive isoforms. Exons for the two transcripts are labeled in order, 5′ to 3′, with protein sequence and Uniprot features (UPF) or InterPro regions (IPR) corresponding to each exon displayed above or below them. Yellow filled boxes indicate domains and motifs differing between the competitive isoforms. (D) Domains and motifs directly aligning to a probe set’s genomic position. A theoretical probe set aligning to the intron of a gene is shown. InterPro domains/motifs whose genomic position (genomic exon start and exon end position) overlaps with a given probe set (genomic start and end position) are shown with a yellow filled box. Rather than comparison of two protein sequences with the competitive isoform analysis, only a single protein sequence is required for the direct genomic alignment method.

doi:10.1371/journal.pcbi.1000553.g002
Comparison of hESC-Derived Cardiac and Neural Progenitors to Adult Tissues

To identify genes with common CP-NP differentiation or CP-specific AS patterns, we isolated homogenous populations of hESCs and cardiac precursors and compared them to a dataset of neural precursor differentiation [10]. To determine the relationship between undifferentiated, progenitor and adult tissues, we performed an unbiased analysis using expression clustering and an analysis of cell-specific marker gene expression.

Homogenous populations of undifferentiated hESCs and CPs were isolated by modifying the H9 ESC line to stably express neomycin-and puromycin-resistance genes, driven by the pluripotent-cell-specific REX-1 and CP-specific myosin heavy chain alpha (MHCα or MHY6) promoters, respectively (see Materials and Methods). In embryoid bodies that underwent puromycin selection and were differentiated for 40 days, the action potentials and axial force measurements of the resulting CPs were similar to those of normal fetal cardiomyocytes [11]. RNA harvested from REX+ hESCs and CPs was analyzed with Affymetrix human exon 1.0 arrays; these data were combined with a dataset of two published hESC lines (Cythera and HUES6) and NPs derived from these hESCs [10] and a dataset of 11 adult human tissues [13].

Gene expression values from these exon arrays were determined for constitutive aligning or all probe sets for each Ensembl gene (Materials and Methods). As shown by hierarchical clustering of these gene expression profiles, the three hESC lines (H9, Cythera, and HUES6) were more closely correlated to each other than to their differentiated progenitors or adult tissues (Figure 1A). However, CPs and NPs, while more closely correlated to each other and undifferentiated hESCs, were less correlated to their in vivo tissue counterparts (heart and cerebellum). For several reasons, such differences are not unexpected; adult tissues are composed of a variety of cell types, passaged cell lines were compared to adult cells, the arrays were processed in different laboratories, and the cells are of distinct genetic origins. Although gene expression profiles of CPs were not closely correlated with samples from adult heart, CP gene expression levels were similar to those of adult heart for all cardiac markers examined (Figure 1B). Both NP lines express neuron-specific markers [10]. Thus, these progenitor cells are closely related to hESCs but retain cell-type-specific marker expression and therefore are appropriate cell systems for assessing AS and differentiation into cardiac and neural lineages.

AS Is a Key Feature of CP Differentiation

To identify alternative exons in days 40 CPs versus REX+ hESCs and link the results to predicted sequence changes that might alter protein expression/function, we created a free, open-source application called AltAnalyze (http://www.AltAnalyze.org) (Materials and Methods). For exon array analysis, AltAnalyze uses the SI approach [19,20] to calculate a probe set fold change corrected for gene-expression and corresponding SI t test and MiDAS p values. To identify higher-confidence alternative exons, only regulated probe sets overlapping with exons in annotated mRNAs (Ensembl or UCSC Genome Browser, including retained introns) were used for further analyses.

Of the 13,583 genes with evidence of expression, 16% (2,106) were predicted to have at least one alternative exon in the differentiation to CPs, as compared to 3,044 genes with up- or downregulated gene expression (Table 1). Of the alternatively regulated genes (ARGs) containing one or more alternative exons, 42% (876) had alternative exons with prior evidence of AS (defined here as alternative or mutually exclusive cassette exons, alternative splice sites, exon-bleeding [15], alternative-C-terminal exons or retained introns; see Figure 2A), 8% (170) had an alternative promoter (AP), and 7% (152) had both; the remainder occurred in constitutive exons (Dataset S2). Thus, our analysis predicts that 3% of all Ensembl genes examined (876 of 29,151) are alternatively spliced relative to 10% (3,044 of 29,151) differentially expressed during the differentiation of hESCs to CPs.

Results and Discussion

Comparison of hESC-Derived Cardiac and Neural Progenitors to Adult Tissues

To identify genes with common CP-NP differentiation or CP-specific AS patterns, we isolated homogenous populations of hESCs and cardiac precursors and compared them to a dataset of neural precursor differentiation [10]. To determine the relationship between undifferentiated, progenitor and adult tissues, we performed an unbiased analysis using expression clustering and an analysis of cell-specific marker gene expression.

Homogenous populations of undifferentiated hESCs and CPs were isolated by modifying the H9 ESC line to stably express neomycin-and puromycin-resistance genes, driven by the pluripotent-cell-specific REX-1 and CP-specific myosin heavy chain alpha (MHCα or MHY6) promoters, respectively (see Materials and Methods). In embryoid bodies that underwent puromycin selection and were differentiated for 40 days, the action potentials and axial force measurements of the resulting CPs were similar to those of normal fetal cardiomyocytes [11]. RNA harvested from REX+ hESCs and CPs was analyzed with Affymetrix human exon 1.0 arrays; these data were combined with a dataset of two published hESC lines (Cythera and HUES6) and NPs derived from these hESCs [10] and a dataset of 11 adult human tissues [13].

Gene expression values from these exon arrays were determined for constitutive aligning or all probe sets for each Ensembl gene (Materials and Methods). As shown by hierarchical clustering these gene expression profiles, the three hESC lines (H9, Cythera, and HUES6) were more closely correlated to each other than to their differentiated progenitors or adult tissues (Figure 1A). However, CPs and NPs, while more closely correlated to each other and undifferentiated hESCs, were less correlated to their in vivo tissue counterparts (heart and cerebellum). For several reasons, such differences are not unexpected; adult tissues are composed of a variety of cell types, passaged cell lines were compared to adult cells, the arrays were processed in different laboratories, and the cells are of distinct genetic origins. Although gene expression profiles of CPs were not closely correlated with samples from adult heart, CP gene expression levels were similar to those of adult heart for all cardiac markers examined (Figure 1B). Both NP lines express neuron-specific markers [10]. Thus, these progenitor cells are closely related to hESCs but retain cell-type-specific marker expression and therefore are appropriate cell systems for assessing AS and differentiation into cardiac and neural lineages.

AS Is a Key Feature of CP Differentiation

To identify alternative exons in days 40 CPs versus REX+ hESCs and link the results to predicted sequence changes that might alter protein expression/function, we created a free, open-source application called AltAnalyze (http://www.AltAnalyze.org) (Materials and Methods). For exon array analysis, AltAnalyze uses the SI approach [19,20] to calculate a probe set fold change corrected for gene-expression and corresponding SI t test and MiDAS p values. To identify higher-confidence alternative exons, only regulated probe sets overlapping with exons in annotated mRNAs (Ensembl or UCSC Genome Browser, including retained introns) were used for further analyses.

Of the 13,583 genes with evidence of expression, 16% (2,106) were predicted to have at least one alternative exon in the differentiation to CPs, as compared to 3,044 genes with up- or downregulated gene expression (Table 1). Of the alternatively regulated genes (ARGs) containing one or more alternative exons, 42% (876) had alternative exons with prior evidence of AS (defined here as alternative or mutually exclusive cassette exons, alternative splice sites, exon-bleeding [15], alternative-C-terminal exons or retained introns; see Figure 2A), 8% (170) had an alternative promoter (AP), and 7% (152) had both; the remainder occurred in constitutive exons (Dataset S2). Thus, our analysis predicts that 3% of all Ensembl genes examined (876 of 29,151) are alternatively spliced relative to 10% (3,044 of 29,151) differentially expressed during the differentiation of hESCs to CPs.
Table 1. Alternative gene regulation during CP differentiation.

| Genes (n) | Genes examined (n) |
|-----------|-------------------|
| Differentially expressed genes | 3,044 | 29,151 |
| Genes with alternative exons (ARGs) | 2,106 | 13,583 |
| Alternative splicing (AS) | 876 |
| Alternative promoter (AP) | 170 |
| AS and AP | 152 |
| No evidence of AS or AP | 908 |

Number of genes differentially expressed and alternatively spliced. Gene expression values were calculated for 29,151 Ensembl gene identifiers, of which only 13,583 were examined for AS. Genes examined for AS were required to have constitutive annotated probe sets expressed in both undifferentiated H9 ESCs and derived CPs. Transcriptional activity of genes was determined by using either constitutive probe sets, if present, or all probe sets, when not present. Genes with alternative exons are unique Ensembl genes reported by AltAnalyze with alternatively expressed probe sets. Genes with alternative exons only aligning to AS annotations or only to AP annotations are reported along with genes that associate with both AS and AP (multiple exons or one exon with multiple annotations) and no evidence of AS or AP.

doi:10.1371/journal.pcbi.1000553.t001

As in earlier studies of NP differentiation [10], pathway analysis of all alternative exons showed that serine/threonine protein kinases and genes with helicase activity were highly enriched during differentiation to CPs. We also found over-representation of actin cytoskeleton, RNA splicing, cell-cell adherens junction, chromatin binding, regulation of muscle contraction, and cell cycle checkpoint genes, among others, using the program GO-Elite (Dataset S4).

Assessing the Impact of AS on Protein Domain and miRNA Binding Site Architecture

Although analysis of protein composition determined by AS is not entirely novel [32,33], AltAnalyze has many novel features. For example, it incorporates protein, domain, and motif information from multiple protein annotation databases (UniProt, InterPro), detailed information on the competitive isoforms analyzed, and analyses of miRNA binding site predictions from multiple databases (PicTar, miRbase, miRanda and TargetScan). By default, domain/motif predictions are derived by comparing two protein isoform sequences—one that aligns to the alternative exon and another in which the exon is absent from the corresponding miRNA sequences (competitive isoforms). Since many aligning and nonaligning miRNAs can exist for each alternative exon, an algorithm is used to identify isoform pairs with the smallest differences in exon composition (Figure 2B). Identification of the corresponding protein (Ensembl or NCBI) or in silico translation of these competitive isoforms allows AltAnalyze to identify protein domain or motif sequences (InterPro and UniProt) that differ in the inclusion of a target exon between the two isoforms (competitive isoform analysis) (Figure 2C). An alternative method analyzing domain/motif regulation is also used, whereby the genomic coordinates of probe sets that correspond to an alternative exon are compared to the genomic position of all InterPro domains and motifs for that gene (direct genomic alignment) (Figure 2D and Text S1). Since AltAnalyze is a freely distributed software package, these analyses can easily be applied to any exon-array dataset.

Table 2. Regulation of miRNA binding sites during CP differentiation.

| Genes (n) | Total genes (n) |
|-----------|----------------|
| Differentially expressed miRNAs | 26 | 216 |
| ARGs with miRNA binding sites | 264 | 11,085 |
| Upregulated in hESCs | 202 |
| Downregulated in hESCs | 60 |
| Up- and downregulated in hESCs | 2 |

Transcriptionally regulated genes annotated as miRNAs and genes containing alternative exons overlapping with predicted miRNA binding sites. Analysis of gene transcription data from the Affymetrix exon array, highlights 26 Ensembl annotated miRNA genes differentially expressed with CP differentiation (up- or downregulated $p < 0.05$) out of 216 probed on the array and in Ensembl. Of the 13,583 genes analyzed for alternative exon expression, 11,085 had probe sets containing at least one predicted miRNA binding site. The pattern of alternative exon expression is indicated for hESCs relative to CPs. Upregulation indicates that the alternative exon containing a putative miRNA binding site is expressed at a higher level in hESCs than CPs, relative to constitutive expression levels. Genes with up- and downregulation of miRNA binding sites indicates that more than one alternative exon with miRNA binding site(s) was present having opposite expression patterns.

doi:10.1371/journal.pcbi.1000553.t002

AS Modifies Predicted Protein Domain and miRNA Binding Site Architecture during Cardiac Differentiation

For alternative exons regulated during CP differentiation, predicted changes in domain/motif and miRNA binding site composition were examined with AltAnalyze. The majority of alternative exons during CP differentiation (79%), corresponded to competitive miRNA isoforms (sharing some exons, but not the probed exon) (Materials and Methods) (Dataset S2). Competitive isoform analysis predicted that one or more protein domains/motifs would be modified or absent in 62% of alternative exons. But with the direct genomic alignment method, only 32% of the alternative exons were predicted to affect domains/motifs. Although 27% of the direct genomic alignment predictions only occurred with this prediction method, these typically occurred in constitutive regions with no competitive isoforms identified. Thus, many of the domain/motif changes predict by competitive isoform analysis occurred as result of indirect protein differences (e.g., protein truncation), while others could only be identified with the direct genomic alignment method.

To determine whether certain domains or motifs were over-represented by both methods, we examined the associated over-representation z scores and permutation-based p values for all CP differentiation ARGs (Materials and Methods). Using either the competitive isoform or direct genomic alignment methods, AltAnalyze identified over-representation of the laminin globular domain, myosin head motor region, and spectrin, plectin, collagen triple helix and rho-binding repeats. In addition, competitive isoform analysis alone identified the KCNQ, C-terminal and metalloprotease regions, and the actin-binding, spectrin-actin binding, KH, CUB, FERM, IQ, SH3, and protein kinase domains. Direct genomic alignment identified the START lipid-binding, semaphorin and Dbl homology domains, among others. Several of these same elements were also enriched with the AltAnalyze analysis of NP differentiation, including spectrin repeats and CUB, FERM, IQ, SH3, and the laminin globular and actin-binding domains (Datasets S2 and S3).

In addition to protein domains/motifs, 12.5% of ARGs associated with CP differentiation (264 of 2,106) resulted in the predicted gain or loss of at least one miRNA binding site (Table 2).
Nearly half of the miRNA binding site changes (129 of 264) were in an exon with evidence of AS, often as a result of intron retention, exon bleeding, or an alternative C-terminus; the remainder were in a constitutive exon with a variable 3’ length and thus are not likely due to AS (Dataset S2).

Interestingly, a recent study also observed alternative expression of exon regions containing miRNA binding sites, when these cells began to actively divide [34]. This study was performed with the mouse Affymetrix exon array and revealed shorter untranslated regions (UTRs) and fewer miRNA binding sites in the mRNAs of proliferating CD4 positive T lymphocytes. Similarly, fewer predicted miRNA binding sites were found in pluripotent REX+ hESCs than in CPs (204 downregulated alternative exons with binding sites in hESCs out of 264, \( \chi^2 p<0.01 \)). The same trend was observed for NPs versus hESCs (Datasets S2 and S3). Thus, a loss of miRNA binding sites may be common to actively dividing cells. Using the same analysis applied to domains and motifs, only one miRNA binding site was over-represented among ARGs in CP differentiation (hsa-miR-219) and only one for NP differentiation (hsa-miR-407a). Neither miRNA has previously been associated with ESC differentiation.

AltAnalyze Identifies Known Differentiation Splicing Events That Correlate with Altered Protein Function

Several predicted splicing events identified in CPs were verified in previous analyses of hESC differentiation. These included genes that underwent AS in the differentiation to NPs (SLK, SORB1 [10], and NFYA [35]) and in cardiac/muscle differentiation (ATP2A2 [36,37], NF1 [38], PKM2 [39], and ANXA7 [40]). SLK had one of the largest exon inclusion SI scores in hESCs, and ANXA7 had one of the largest in CPs. RT-PCR analysis of six of these AS events (ANXA7, ATP2A2, NF1, PKM2, SLK, and VCL) in REX+ hESCs and CPs verified the expected changes in isoform expression (Figure 3A–C).

At least three of these verified AS events correspond to modified protein function/expression, producing differences in cell metab-
olism (PKM2) [41,42], signaling (VCL) [43], or mRNA stability (ATP2A2) [36]. In each case, AltAnalyze predicted the regulation of protein domains or motifs previously associated with these differences. In the case of PKM2 or pyruvate kinase, two isoforms (M1 and M2) are expressed through mutually exclusive splicing (mutual gain and loss of a cassette exon) [39]. Although the two alternatively spliced exons are the same length (167 base pairs) and have 60% protein sequence identity to each other, they differ in their tissue developmental expression patterns, protein motif composition, and in vito functions [39]. M1 is largely present in normal adult heart, skeletal muscle, and brain and is not allosterically regulated by fructose-1,6-bisphosphate (FBP). M2 is present only during embryonic development and in tumors, is regulated by FBP, and promotes proliferation [41,42]. Isoform expression levels and protein predictions by AltAnalyze matched the previously identified motif changes corresponding to functionally relevant differences in these proteins (loss of the UniProt-defined FBP binding region and intersubunit contact and upregulation of the M1 exon in CPs) (Figure 3D).

For vinculin (VCL), the gain of a vinculin/alpha-catenin sequence by AS is associated with altered ligand binding properties of the muscle form of the protein [43]. For this same alternative exon, AltAnalyze predicted the same previously reported protein sequence difference. For ATP2A2 (cardiac sarco/endoplasmic reticulum calcium ATPase), intron retention of 4068 base pairs before the last exon increases the length of the cytoplasmic topological domain (45 amino acids [aa]) and 3’ UTR. Expression of the long C-terminal form (isoform 2b) of ATP2A2 [hESC-enriched] increases mRNA degradation of this transcript in vito [36]. AltAnalyze similarly predicted that this AS event would increase the length of the cytoplasmic topological domain (UniProt), in addition to the inclusion of several putative miRNA binding sites (hsa-miRNA-429, 200b, and 182), each supported by evidence from multiple miRNA binding site prediction algorithms (Figure 3E). CPs had decreased expression of the retained intron containing these miRNA binding sites relative to hESCs. Interestingly, two of these miRNAs, miRNA-200b and miRNA-182, were highly enriched in CPs derived from mouse ESGs [44], suggesting a possible mechanism for the increased degradation of the long 3’UTR form. Thus, AltAnalyze suggested a new mechanism for the regulation of ATP2A2 expression by AS.

**Regulation of Distinct Pathways for Cardiac- and Differentiation-Associated Splicing Events**

The combination of cardiac and neural differentiation data provides a unique opportunity to define molecular profiles unique to or in common to specific differentiation paradigms. To identify AS events during CP differentiation that correspond to CP-specification or inhibition/promotion of differentiation, we used two-way ANOVA to compare alternative isoform expression between cardiac and neural differentiation (Materials and Methods). Considering the large number of well-characterized cardiac, neural, and hESC markers, we initially applied this method to transcriptionally regulated genes for the two differentiation paradigms. Of 3,044 differentially expressed CP genes, 1,962 had a common CP-NP differentiation expression pattern in cardiac and neural differentiation (differentiation p<0.05), and 951 were preferentially regulated during CP differentiation (interaction p<0.05). As predicted, genes with the lowest ANOVA differentiation (common to CP and NP differentiation) p value corresponded to key pluripotency factors (e.g., LIN28, OCT3/4) and pathways (cell cycle control and regulation of pluripotency). Likewise, genes with the lowest ANOVA interaction (differing in CP and NP differentiation) p value corresponded to well-described cardiac markers (e.g., TNNC1, TNNH1, TNNI3, MYH6, MYH7, PLN, GATA4, GATA6, NPPA, TBX3, TBX20) and pathways (early cardiac developmental, muscle proliferation, cardiac muscle contraction) when analyzed with GO-Elite (Figure S1).

When applied to alternative exons regulated during CP differentiation, this ANOVA method identified 563 genes with a common CP-NP differentiation expression pattern and 414 genes with a CP-specific expression pattern (Figure 4A, B). In both groups, we considered only alternative exons associated with AS annotations by AltAnalyze. Three AS events identified from previous studies (SORBS1, SLK, and ATP2A2) were among the top 26 ranked genes (ANOVA p in the two expression pattern groups examined.

When pathway analysis was applied to AS genes with a common CP-NP differentiation splicing pattern, the most enriched ontology categories/pathways were water binding, RNA and chromatin binding, integrin-mediated signaling, microtubule binding, extracellular matrix, and lipid transport (Figure 4C). In contrast, AS genes with a CP-specific pattern were enriched in pathways for phosphatidylinositol binding, sarcoplasmic reticulum, negative regulation of neurogenesis, regulation of heart contraction, Wnt receptor signaling, and regulation of cyclin-dependent protein kinase activity. Both sets were enriched in serine/threonine kinases, helicases, actin cytoskeletal, RNA splicing, and cell cycle checkpoint genes (Figure 4D and Dataset S4). These results imply that the loss of pluripotency corresponds to AS genes that regulate transcription, cell-cell contact formation, and metabolism, while cardiac-enriched events favor contractile pathways, inhibition of neurogenesis, and Wnt signaling (Dataset S4).

**Confirmation of CP Differentiation AS by RT-PCR**

Fifty alternative exons with a CP-specific or common CP-NP differentiation pattern were selected for further confirmation and in-depth analysis of domain/miRNA binding sites. When applied to a previously described dataset with comprehensive validation (knockdown of the splicing factor PTB) [45], AltAnalyze identified a high percentage of true-positive splicing events (Text S2). To better assess the impact of splicing on predicted domain/miRNA binding site composition, genes containing such predictions with few alternative exons were preferentially tested. RT-PCR analysis confirmed 44 of the 50 target alternative exons, with 37 displaying significantly larger shifts in isoform expression than the rest (Figure 5 and Figure S2). The six failed primer sets produced either inconclusive results or missing PCR products. For all genes except VCL, only one alternative exon per gene was tested, even if multiple exons were predicted.

Genes with some of the most pronounced confirmed changes and a common CP-NP differentiation AS pattern included those encoding serine/threonine kinases (SLK, FER, FYN, MARK3), spectrin-actin binding (SPTBN1, ADD3), cell cycle (MADD, PGBP4, SEPT6), and cell-cell communication (TJP1) proteins. Similarly regulated genes with a CP-specific AS pattern included those encoding calcium signaling (ASPH, ANXA7, ATP2A2), cell metabolism (PKM2, OGDH), cell cycle (NUMB, UBE4B, CSDE1, NF1, ANXA7), and double-stranded RNA binding (STAU1) proteins. Several of these confirmed AS events appeared to have cardiac/muscle-specific and common CP-NP differentiation patterns when examined with the entire adult tissue/cell line exon-array panel. This was the case for the genes KIF13A and CSDE1, each of which showed the highest alternative exon expression for hESCs or cardiac/muscle cells, respectively, when compared to all other tissues and cells (Figure 6A–B). Thus, most of the examined alternative exons have expression patterns
consistent with those predicted by AltAnalyze and appear to mimic those in adult tissues.

Identifying Splicing Events Predicted to Modify Protein Function

The possible effects of AS on protein function are diverse and therefore challenging to predict bioinformatically. Since AltAnalyze identified confirmed domain/motif changes that correlate with changes in protein function (e.g., PKM2 [41,42] and VCL [43]), we chose to further explore AltAnalyze’s predictions for the 44 confirmed alternative exons. These analyses are useful for evaluating how splicing may impact protein domain/motif inclusion and composition for future validation studies.

High Degree of Specificity of Domain-Level Protein Predictions

Of the 44 confirmed splicing events for CP differentiation, 34 were initially predicted to alter protein domain or motif composition (Table 3). Although validation of these events requires careful in vitro analyses, to evaluate the specificity of AltAnalyze
protein predictions, we examined the genomic overlap of an alternative exon with domains/motifs (direct genomic alignment) and performed a more exhaustive competitive protein analysis to determine whether any comparisons yield an absence of changes in domain/motif composition (Text S1). This exhaustive method examines all possible competitive protein isoform pairs and selects the pair that produces the smallest overall differences in protein sequence and domain/motif predictions.

Twenty-two of the 34 alternative exons were predicted to have domain/motif changes with both direct genomic alignment and competitive isoform analysis. These alternative exons should directly change the sequence or disrupt a domain/motif and thus represent higher-confidence predictions. Only one gene, LEFTY1, was predicted to alter the sequence of a domain (transforming growth factor β) with direct genomic alignment and not the competitive isoform analysis. In all but four of these 34 alternative exons, changes in domain/motif composition were also predicted by the exhaustive comparison method. Three of these four alternative exons were present in both untranslated and coding regions of the different possible isoforms. Since the exhaustive method is biased towards selection of competitive isoforms that produce no change in domain/motif composition, only competitive isoforms where the alternative exon was present in an untranslated region were selected. Of the remaining 30 alternative exons, 17 had identical domain/motif predictions with the exhaustive and the original competitive isoform analysis and 13 had almost identical predictions (largely the same but sometimes fewer domain/motif changes) with the exhaustive method (Dataset S2). Thus, several of the domain/motif changes were only found with the competitive isoform analysis and not with direct genomic alignment or the exhaustive methods. However, it is unclear which predictions are false positives, since AS of a single exon could theoretically co-segregate with other AS or AP events in the same transcript.

Impact of Domain-Level Predictions on Known Biology

Predicted changes in protein domain/motif composition for confirmed splice events could be classified into four groups: truncation, disruption, modification, exchange or no associated predictions. For protein truncation or disruption, we can infer potential functional consequences of the domain/motif change based on known biology of the protein and its interactions. For exchange or modification, we can only speculate that the protein function differs from that of the characterized isoform(s).

Protein Truncation with CP Differentiation

Nine of the confirmed AS events (CDC42, CLK1, EWSR1, FER, HDAC9, LRRFIP1, OGDH, VCL (exon 10-2), and WNK2) were predicted to introduce a premature stop-codon into the transcript, causing either protein truncation (>30% decrease in protein length) or absence of translation (e.g., nonsense-mediated decay) [6]. In the majority of cases, except for FER and LRRFIP1, no protein sequence was found in public databases for the truncated isoform; therefore, AltAnalyze produced theoretical protein sequences based on in silico translation. In four cases (WNK2, CLK1, HDAC9, EWSR1), the in silico predicted
protein was 2–30% of the length of the competitive isoform and thus likely not to be translated. In addition to these C-terminally truncated proteins, N-terminal truncation of CDC42BPA, HIF3A and NAV2 resulted in substantially shorter protein sequences (35–39%) with a resulting loss in domain/motif predictions. There did not appear to be a bias towards increased protein truncation in CPs or hESCs.

Since these splicing events are predicted to significantly reduce protein size and domain/motif composition, there is a much higher likelihood that these changes would disrupt protein function or prevent protein translation. For example, in cardiomyocytes, the large upregulation (~8-fold by AltAnalyze) of a cassette exon in the histone deacetylase HDAC9 protein is predicted to truncate the reference isoform from 1066 to 21 aa. HDAC9 typically represses expression of myocyte enhancer factor 2 (MEF2), a potent cardiac inducing transcription factor [46]. Truncation or more likely absence of translation should thus alleviate HDAC9's repressive action on MEF2 transcription factors to promote cardiogenesis. Among the four MEF2 family members examined in this analysis, three were transcriptionally upregulated, with MEF2C increased 51-fold in CPs versus ESCs. In the case of hypoxia-inducible factor-3 (HIF3A) (common CP-NP differentiation pattern), the putative truncated isoform (lower band by RT-PCR) was expressed in both hESCs and CPs, while the full-length isoform was largely restricted to CPs. The truncated form of HIF3A, resulting from selection of an alternative 5’ splice site, is predicted to disrupt the DNA-binding, PAS, and nuclear translocation domains and the helix-loop-helix motif. HIF3A participates in the adaptive response to hypoxia as a transcriptional regulator of downstream genes [47]. The precise function of this variant is unclear, but its exon and domain structure are similar to those of a mouse variant of this gene called inhibitory PAS domain protein, a dominant-negative regulator of HIF3A transcription [47]. Thus, splicing of HIF3A may play a critical role in regulating hypoxic responses in pluripotent versus differentiated cells.

Disruption of Domains and Motifs with CP Differentiation

In addition to protein truncation, removal of protein sequences was also predicted to disrupt domains and motifs in 10 of the confirmed AS events (ABI2, ANXA7, ASPH, ATP2A2, KIF13A, NEDD4, PCBP4, SPTBN1, STAU1, and UBE4B). In CPs, these predictions include the disruption of the C2 calcium-dependent membrane targeting domain in the NEDD4 protein with exclusion of a 72-aa block of exons; intron retention in the PCBP4 gene, which produces a shorter N-terminus that disrupts a KH domain; and the disruption of a phosphopantetheine attachment site in the UBE4B protein with the insertion of a cassette exon encoding 129 aa. In hESCs, the disruption of presumptive domains was observed with the exclusion of 61-aa-encoding exon in the ABI2 protein that eliminated the predicted presence of a neutrophil cytosol factor domain; and removal of the first 9 aa from the double-stranded DNA binding domain in the STAU1 gene.

Since these domains are crucial for the annotated functions of these genes, the predicted sequence loss or disruption could affect their function considerably. An example is PCBP4, an RNA-binding protein and regulator of apoptosis characterized by presence of a KH domain. PCBP4 with an intact KH domain can suppress cell proliferation by inducing apoptosis, but is largely absent in hESCs. Since PCBP4 has a common CP-NP differentiation-splicing pattern, AS of this gene may be important in maintaining pluripotency in hESCs.

Two other, genes aspartyl beta-hydroxylase (ASPH) and spectrin, beta, non-erythrocytic 1 (SPTBN1) both had prior evidence of functionally distinct splice variants, linked in this case to the regulation of cardiac physiology. In the case of ASPH, the cardiac-enriched form specifically complexes with cardiac con-

Figure 6. Comparison of differentiation and tissue AS patterns. (A) For the genes KIF13A and CAPZB, log2 expression values for exon aligning probe sets are shown; probe sets are ranked in order of genomic position on the x-axis and expression values are plotted on the y-axis. (B) For both genes, relative exon-inclusion is assessed for CP and NP differentiation conditions and 11 adult tissue conditions by plotting the mean constitutive gene expression (y-axis) against the expression of the interrogated alternative exon (x-axis). Each diamond represents a distinct tissue. For KIF13A, exon 41 (E41) is most highly expressed in the hESC lines (H9 and Cythera), suggesting E41 inclusion is greatest in hESCs. For CAPZB, exon 12 (E12) is most highly expressed in muscle (CP, heart and muscle). H9 = REX+ hESC, Cy = Cythera hESCs, Mus = muscle, Hrt = heart.

doi:10.1371/journal.pcbi.1000553.g006
### Table 3. AltAnalyze functional predictions for confirmed CP differentiation AS events.

| Gene symbol | ANOVA pattern | SI | Exon ID | GE fold Δ | Exon annotations | Δ protein length | Primary functional change |
|-------------|---------------|----|---------|-----------|------------------|------------------|--------------------------|
| CSD1       | cardiac       | 0.01| E3      | 0.05      | cassette exon    | 767->767         | Kinase (gain), H+ acceptor (loss) |
| MADD       | diff          | 0.04| E28     | 0.24      | cassette exon    | 1608->1581       | Kinase, H+ acceptor (loss) |
| PCBP4      | diff          | 0.07| E57     | 1.07      | cassette exon    | 2127->2145       | Kinase, H+ acceptor (loss) |
| NUMB       | diff          | 0.01| E14     | 1.0        | cassette exon    | 651->603         | Kinase, H+ acceptor (loss) |
| SAPS2      | diff          | 0.02| E3[E4]  | 0.17      | cassette exon    | 932->966         | Kinase, H+ acceptor (loss) |

**Transcript Truncation**

| Gene symbol | ANOVA pattern | SI | Exon ID | GE fold Δ | Exon annotations | Δ protein length | Primary functional change |
|-------------|---------------|----|---------|-----------|------------------|------------------|--------------------------|
| CDC42       | diff          | 0.01| E9-1    | 0.25      | alt-C-term       | 116->191         | miRNA, GTPase Rab/Ras/Rho (gain) |
| CDC42BPA    | cardiac       | 0.01| E37     | 0.28      | cassette exon    | 1719->1045       | Kinase (loss), PAK box Rho BIND (gain/loss) |
| CLK1        | cardiac       | 0.01| I7      | 0.4       | intron-retention | 454->134         | Kinase, H+ acceptor (loss) |
| EWSR1       | cardiac       | 0.01| E16-2   | 0.3       | intron-retention | 600->146         | DNA BIND, RRM (loss) |
| HDAC9       | cardiac       | 0.01| E4      | 0.78      | cassette exon    | 1066->21         | Interaction w/MEF2, HDAC region (loss) |
| HIF3A       | diff          | 0.01| E8-3    | 0.06      | Alt-5'           | 237->363         | DNA BIND, HLH, PAS, Nuc_translocat (gain) |
| LRRFIP1     | cardiac       | 0.01| E5 to E9| 0.68      | cassette exon    | 752->640         | DNA BIND, PT, PS (loss) |
| NAV2        | diff          | 0.01| E21[E22]| 0.77      | cassette exon    | 1493->2429       | Calponin_act_bd, Na_channel4 (gain) |
| OGDH        | cardiac       | 0.01| E6      | 0.04      | cassette exon    | 1023->567        | 2 oxoglutarate_DH_E1, Transketo_Cen_R (loss) |
| WNK2        | diff          | 0.01| E28     | 0.28      | cassette exon    | 45->1004         | Kinase, H+ acceptor, PS (gain) |
| FER         | diff          | 0.01| E4      | 1.54      | cassette exon    | 163->822         | Kinase, H+ acceptor, SH2 (gain) |

**Disrupted Domains/Motifs Sequences**

| Gene symbol | ANOVA pattern | SI | Exon ID | GE fold Δ | Exon annotations | Δ protein length | Primary functional change |
|-------------|---------------|----|---------|-----------|------------------|------------------|--------------------------|
| AB2         | cardiac       | 0.01| E9      | 0.2       | miRNA, Asp-b-hydro N-term (gain/loss), Cytoplasmic/Lumenal Topo, PS (loss) |
| ANXA7       | cardiac       | 0.01| E6      | 0.32      | Annexin (gain/loss), Pro-rich (loss) |
| ASPH        | cardiac       | 0.01| E7[E8]  | 0.96      | miRNA, Asp-b-hydro N-term (gain/loss), Cytoplasmic/Lumenal Topo, PS (loss) |
| ATP2A2      | cardiac       | 0.01| E20[E22]| 1.38      | bleedingExon     | 1042->997        | miRNA, Cytoplasmic Topo (loss) |
| KIF13A      | diff          | 0.01| E41     | 1         | miRNA (gain), Carbohyd-O-linked, Spectrin, PH (loss) |
| NEDD4       | diff          | 0.01| E7      | 0.02      | miRNA (gain), Carbohyd-O-linked, Spectrin, PH (loss) |
| PEBP4       | diff          | 0.01| E6-3    | 0.39      | miRNA (gain), Carbohyd-O-linked, Spectrin, PH (loss) |
| SPTBN1      | diff          | 0.01| E34-2   | 0.45      | bleedingExon     | 2377->2155       | miRNA (gain), Carbohyd-O-linked, Spectrin, PH (loss) |
| STAU1       | diff          | 0.01| E7      | 0.04      | miRNA (gain), Carbohyd-O-linked, Spectrin, PH (loss) |
| UBE4B       | cardiac       | 0.01| E9      | 0.41      | miRNA (gain), Carbohyd-O-linked, Spectrin, PH (loss) |

**Exchanged Domain/Motif Sequences**

| Gene symbol | ANOVA pattern | SI | Exon ID | GE fold Δ | Exon annotations | Δ protein length | Primary functional change |
|-------------|---------------|----|---------|-----------|------------------|------------------|--------------------------|
| FYN         | diff          | 0.01| E12     | 0.1       | C2 Domain (loss) |
| PKM2        | diff          | 0.01| E12     | 0.32      | C2 Domain (loss) |
| TCF3        | diff          | 0.01| E18     | 0.75      | C2 Domain (loss) |

**Modified Domain/Motif Sequences**

| Gene symbol | ANOVA pattern | SI | Exon ID | GE fold Δ | Exon annotations | Δ protein length | Primary functional change |
|-------------|---------------|----|---------|-----------|------------------|------------------|--------------------------|
| ADD3        | diff          | 0.01| E16     | 0.26      | miRNA (gain/loss) |
| CAPZB       | diff          | 0.01| E12     | 0.21      | miRNA (gain/loss) |
| DNMT1       | cardiac       | 0.01| E3      | 0.3       | miRNA (gain/loss) |
| HISPPD2A    | diff          | 0.01| E49-1   | 0.17      | miRNA (gain/loss) |
| MARK3       | diff          | 0.01| E19     | 0.04      | miRNA (gain/loss) |
| SLK         | diff          | 0.01| E15     | 0.64      | miRNA (gain/loss) |
| TJP1        | diff          | 0.01| E24     | 0.03      | miRNA (gain/loss) |
| VCL         | diff          | 0.01| E23     | 0.1       | miRNA (gain/loss) |
| VPS39       | Diff          | 0.01| E3      | 0.08      | miRNA (gain/loss) |

**miR binding site(s)**

| Gene symbol | ANOVA pattern | SI | Exon ID | GE fold Δ | Exon annotations | Δ protein length | Primary functional change |
|-------------|---------------|----|---------|-----------|------------------|------------------|--------------------------|
| C6orf134    | cardiac       | 0.01| E11     | 0.19      | miRNA (gain)     |
| DER6        | diff          | 0.01| I8      | 0.45      | miRNA (gain)     |
| LEFTY1      | Diff          | 0.01| E4      | 0.68      | miRNA (gain)     |
| MAFB        | Diff          | 0.01| E1-E5   | 0.41      | miRNA (gain)     |
tracheal components (calcestrin, triadin, and the ryano
dine receptor) [48] in the release of sarcoplasmic calcium; in contrast,
the hESC-enriched form is highly expressed in neoplastic cells, has
a distinct cellular localization, and has an additional enzymatic
domain that regulates growth factor activity [49,50]. Proteins
coded by SPTBN1 are found in the sarcosome along the muscle
Z-line and likely contribute to structural stability [51]. Consistent
with AltAnalyze predictions, upregulation of a short form of
SPTBN1 in CPs and NPs is associated with the loss of the
pleckstrin homology domain (producing a loss of inositol-1,4,5
triphosphate binding) [52] and when associated with spectrin
alpha 2, the shorter protein forms more stable tetramers than the
longer protein [53]. Other splicing events had less clear functional
implications on protein sequence, such as the microtubule-
dependent motor protein KIF13A, in which removal of an exon
encoding 35 aa results in the loss of one of three phosphosere
sites indicated by UniProt. If modulated directly by a protein
kinase, however, such a change could alter the regulation of the
resulting protein.

Exchange of Domain Sequences by Mutually Exclusive AS

Unlike the disruption of a critical protein domain, the functional
impact on a domain with an altered sequence is less clear. As
shown in the case of PKM2, mutual-exclusive splicing can alter the
presence of functionally important protein residues without
significant changes in overall protein sequence. This was also the
case for the E2A immunoglobulin enhancer-binding factor TCF3
and for the serine/threonine and protein-tyrosine kinase FYN, in
which a DNA-binding or kinase domain is specifically altered by
the mutually exclusive exchange of a cassette exon of similar
lengths, respectively. Interestingly, the mutually exclusive isofoms
of TCF3 and the FYN have different biochemical properties
[54,55], suggesting that the domain-level alterations predicted by
AltAnalyze correlate with function. In the case of TCF3, although
the DNA-binding domain is 76% identical between the mutually
exclusive isoforms, the hESC-enriched isoform has a longer
DNA-binding affinity than the differentiation-enriched form. Thus,
AS of mutually exclusive exons is a potent means to modify
specific residues within a sequence block without significantly
changing overall protein length.

Modification of Domain/Motif Composition with AS

Although some confirmed AS events significantly changed a
domain sequence, the domain was still called present in both
alternative isoforms. This was the case for nine genes with
confirmed alternative exons (ADD3, CAPZB, DNM1L, HIISPDD2A, MARK3, SLK, TJP1, VCL, and VPS39). Specific
examples include the removal of 32 aa in the C-terminal aldehyde
ferredoxin oxidoreductase domain of the ADD3 protein, insertion
of 13 aa into the dynamin GTPase region of DNM1L,
modification of the C-terminal end of the F-actin capping beta
subunit region of CAPZB, and removal of 11 aa from the N-
terminal Citron homology domain (CNH) of VPS39. In each case,
except VPS39, altering the sequence has unknown consequences
for protein function. VPS39 is a putative adaptor protein that
displays downregulation of a cassette exon in hESCs relative to
CPs. The CNH domain in this protein is required for the
clustering and fusion of late endosomes and lysosomes [56].
Interestingly, the TRAP-1 homologue, the isoform that lacks this
exon, does not mediate lysosomal clustering. Rather, it specifically
associates with the transforming growth factor β signaling
pathway, suggesting that modification of the CNH domain can
alter its signaling properties.

Missing Domain Annotations Affect the Sensitivity of
AltAnalyze Prediction

At least two confirmed AS events (NUMB and MADD) had no
difference in domain-level predictions, but did have known
functional isoforn differences associated with the AS events
[57]. NUMB or the Drosophila orthologue NUMB is involved in
early cell-fate decisions [57] and MADD (MAP-kinase activating
death domain) protein is a membrane-bound cytoplasmatic adaptor
protein that interacts with the TNF-α receptor 1 to transduce
apoptotic signals [58]. Both genes affect pathways of proliferation
and apoptosis. The CP-enriched isoform of NUMB is antiprolifera-
tive, whereas the hESC-enriched form [p71], with a longer
proline-rich region (PRR), retains its proliferative properties
[59,60]. Likewise, expression of the CP-enriched MADD isoform
(IP20) promotes apoptosis, whereas the hESC-enriched isoform
(DENN) is anti-apoptotic and is typically over-expressed in
tumors. These missing annotations were likely due to either an
absence of the domain annotation (PRR) or lack of an associated
domain/motif. These examples illustrate the dependence of
AltAnalyze’s domain/motif predictions on up-to-date and valid
annotations.

Developmental Regulation of miRNA Binding Site
Inclusion by AS

A number of recent studies demonstrated a critical connection
between miRNA expression and the maintenance of pluripotency or
the differentiation of cardiac cells from hESCs. In our exon-
array gene expression analysis, genes for 26 miRNAs were up-
or downregulated during differentiation to CPs and NPs, including
previously implicated pluripotency (mir-302a, 302b) [61] and
cardiac (mir-133, 23b, 26a) [44] regulated miRNAs (Dataset S1).

Table 3. Cont.

| Gene symbol | ANOVA pattern | SI | Exon ID | GE fold ∆ | Exon annotations | Δ protein length | Primary functional change |
|-------------|---------------|----|---------|------------|------------------|------------------|--------------------------|
| SEPT6       | Diff          | 2.4| E11     | 0.59       | cassette exon    | 427->429         | miRNA (loss)             |

Splicing, protein, and miRNA binding site annotations are shown for alternative exons confirmed by RT-PCR. For each alternative exon, the corresponding gene name (Gene symbol), ANOVA AS differentiation pattern (ANOVA pattern: diff = common CP-NP differentiation, cardiac = CP-specific), splicing index (SI) fold change, relative AltAnalyze exon/intron position in the gene structure (Exon ID), gene-expression (GE) fold change (Δ) for the gene, ANOVA AS annotations that correspond to the Exon ID, change in predicted protein length (length of the competitive protein isoforms in hESC->CP), and top corresponding domain/motif or miRNA binding site annotations (Primary functional Δ). Negative SI fold changes indicate increased alternative exon expression in CPs and vice versa. For primary function Δ annotations, gain indicates the increase in the expression of an alternative exon overlapping with that domain in CPs versus hESCs, a loss indicates a relative decrease in expression and a gain/loss indicates that the domain/motif is present in both protein isoforms but with different sequence. PS = phosphoserine modified residue, PT = phosphotyrosine modified residue, miRNA = miRNA binding site. Complete annotations can be found in Dataset S2.

doi:10.1371/journal.pcbi.1000553.t003
Each of these miRNAs was appropriately segregated by ANOVA pattern analysis (Figure 7A).

Although much effort has been devoted to defining the expression patterns and novel targets of miRNAs, little is known about the role of AS in miRNA binding site inclusion in processed mRNA transcripts. Traditional gene expression microarrays focus on the coding regions of transcripts and ignore the noncoding exons, which can be alternatively spliced to produce different C-terminal exons or 3′ UTRs of different lengths. However, exon-tiling arrays allow us to assess mRNA features in tandem with existing predictions for mRNA binding site position on a global basis.

Our analysis identified 264 genes with putative miRNA binding sites that overlap with alternative exons, including those undergoing AS. We tested 10 of these alternative exons by RT-PCR and confirmed nine, including the SPTBN1 and ASPH variants described earlier. Putative miRNA binding sites were included or excluded as a result of alternative cassette exons (ASPH, SEPT6), alternative C-terminal exons (CDC42, C6orf134), bleeding exons (SPTBN1), intron retention (ATP2A2, DERP6), or 3′ UTRs with a longer or shorter sequence (LEFTY1, MAFB) (Figure 7B–D). At least one of these alternative exons (MAFB), with predicted regulation of a mir-130a binding site, is a known target of the predicted miRNA [62] (Figure 7C). In addition to MAFB, several of the putative regulated binding sites were independently predicted by multiple miRNA binding site algorithms (ATP2A2, C6orf134, CDC42, LEFTY1).

Examination of miRNAs with previously established hESC or cardiac differentiation expression patterns identified binding sites for mir-302a, 302c (ESC), and mir-26a (cardiac) in the alternative bleeding exon of SPTBN1 and the aforementioned binding sites in the 3′ UTR of ATP2A2. These data suggest a new, largely AS-dependent mechanism for miRNA regulation of such genes. Since miRNAs can promote and inhibit the translation of targets dependent on cell cycle stage [63], there is the opportunity for complex modes of regulation by these predicted targets in vivo.

Figure 7. Both miRNAs and miRNA binding sites are regulated with hESC differentiation. (A) Expression profiles of two previously characterized miRNAs, mir-302a and mir-133-1, from combined tissue/cell-line gene expression data. (B) RT-PCR isoform expression of genes with putative miRNA binding sites within the regulated probe set. The presence of one or more putative miRNAs is indicated by the notation miR. (C–E) The 3′ region of genes corresponding to three genes are shown, where the regulated isoforms are displayed from the UCSC genome browser along with regulated probe sets and putative miRNA binding site locations. Exons are indicated by thin boxes, UTR regions by thinner boxes and introns by a line with overlapping arrows. Each gene (MAFB, SEPT6, and CDC42) represents distinct possible modes of exon regulation that lead to altered miRNA binding site inclusion: shorter 3′ UTR, alternate cassette exon inclusion, and alternate C-terminal exon. Both MAFB and SETP6 are on the reverse genomic strand, where orientation is 3′ to 5′. The term “multiple algorithms” indicates that two or more miRNA binding site prediction algorithms (PicTar, miRanda, miRBase or TargetScan) predicted a binding site in aligning probe sets.

doi:10.1371/journal.pcbi.1000553.g007
Summary and Conclusions

Using high-density expression profiling, a new method for isolating cardiomyocytes, and novel bioinformatic methods (AltAnalyze), we characterized AS along distinct developmental pathways that influence both pluripotency and the commitment to cardiac and neural lineages. In addition to new insights into these processes, these results offer novel targets for driving the expression of pluripotent cells to distinct lineages and inducing pluripotency from adult cells at the level of specific splice isoforms.

We identified genes that undergo AS during differentiation and observed several global trends which suggest that functional elements, such as protein domains and miRNA binding sites, are coordinately regulated by AS. Many alternative exons highlighted in our analysis were predicted to disrupt or modify functionally important sequences, such as DNA-binding and protein kinase domains that are likely impact protein function. Several of our domain-level predictions also correlated with known changes in protein isoform function or expression as a result of AS [36,41–43]. Thus, AltAnalyze may be useful for identifying AS events that alter protein function/expression by disrupting or modifying protein domains, motifs, or miRNA binding sites.

We identified and confirmed many splicing events that occurred along pathways of apoptosis and proliferation. Two genes confirmed by RT-PCR encode the apoptosis activators PCBP4 and MADD. Isoforms for both genes that induce apoptosis, were downregulated in hESCs but not CPs. Conversely, the proliferation-promoting isoform of NUMB is expressed in hESCs but is undetectable in CPs, while the anti-proliferation isoform is upregulated in CPs, as shown by RT-PCR. These results suggest the intriguing possibility that splicing may coordinate the functional repertoire of distinct members of the same pathway to elicit a biological effect, in this case, self-renewal in hESCs. We also observed AS of the apoptotic regulators CSDE1 and UBE4B along with previously demonstrated tumor suppressor genes ANXA7 [40], EWSR1 [64], and PKM2 [41]. Since both PKM2 and the proto-oncogene EWSR1 directly interact with the pluripotency transcription factor OCT3/4 to promote OCT3/4 activity [41,64], specific isoforms of these genes may also be critical in the regulation of hESC maintenance.

Although only one confirmed CP-specific AS event (ASPH) was clearly linked to the regulation of cardiac physiology, several other novel CP-specific AS events were predicted to alter the composition of critical protein domains (CAPZB, UBE4B, HIF3A, HDAC9). One of the most intriguing was AS of the cardiac inhibitor HDAC9, which results in a highly truncated or nonexpressed form specifically in CPs. These data further support a role for AS in the direct specification of cardiac precursors.

Finally, analysis of the overlap between predicted miRNA binding sites and alternative exons revealed a potential mechanism by which specific cell types may regulate miRNA activity independently of miRNA expression. Such regulation involves AS of exons and differential expression of distal terminal exons, where the mechanism regulating exon length is unclear. Two recent analyses have further demonstrated the interaction between miRNAs and alternatively spliced isoforms [65] or UTRs of different length [34]. Since miRNA expression is thought to fine-tune protein expression downstream of transcription, alternative exon inclusion may be a parallel means of regulating miRNA binding site selection while still retaining full-length protein expression.

While we present several new analyses in this study, it will be essential to experimentally validate these protein and miRNA-level predictions. Additional computational analyses, such as comparative genomic sequence analysis, will also be important for delineating common and distinct cis-regulatory sequences that may regulate cardiac and neuronal splicing. Further refinement of our algorithm to decrease false negatives, similar to other approaches [45,66], will also be important in identifying additional AS events. Finally, future application and refinement of these analyses to additional cell lineages and time points may yield greater resolution of AS events that will likely provide insights into the mechanisms of cell-fate commitment and maintenance of hESC pluripotency.

Supporting Information

Figure S1 Segregation of transcriptional profiles by comparison of neural and cardiac differentiation. Patterns of gene expression are shown for two analyzed pattern groups, (A) common to neural and cardiac differentiation or (B) specific to CPs. Adjacent to each heatmap are the top-ranked genes based on ANOVA p values for each specific pattern; genes highlighted in blue are associated with ESCs or self-renewal, and genes in red with cardiac-specification. Gene Ontology (GO) terms and pathways enriched in the (C) common or (D) cardiac-specific differentiation pattern groups are displayed as compared to the number of associated gene changes in each of the two pattern groups. Asterisks indicate significant GO-Elite scores [permute p<0.01] in the alternate pattern group.

Table S1 Primer sequences for confirmed and non-confirmed AS events.

Text S1 Supplemental methods file. Includes detailed descriptions of algorithms, expression filtering and database architecture of AltAnalyze.

Text S2 Analysis of sensitivity and specificity of AltAnalyze predictions with a publicly available alternative splicing validation dataset (PTB knockdown).

Dataset S1 Gene expression results from the human exon array analysis for all conditions examined. Gene annotations, statistics, ANOVA patterns and log2 expression values provided for all Ensembl genes.

Dataset S2 Alternative exon results for CP differentiation. Multiple spreadsheets are included. Complete probeset- and gene-level results along with microRNA binding site and protein domain/motif over-representation analysis results from AltAn-
lyze are provided. Additional ANOVA pattern, splicing calls and cross-tissue comparison information is included.

Found at: doi:10.1371/journal.pcbi.1000553.s007 (5.20 MB ZIP)

Dataset S3

Alternative exon results for NP differentiation. Multiple spreadsheets are included. Complete probe-set- and gene-level results along with microRNA binding site and protein domain/motif over-representation analysis results from AltAnalysis are provided.

Found at: doi:10.1371/journal.pcbi.1000553.s008 (5.18 MB XLS)

Dataset S4

Gene Ontology and pathway over-representation analyses. The top-scoring terms from GO-Elite are provided for all comparisons.

Found at: doi:10.1371/journal.pcbi.1000553.s009 (0.17 MB XLS)

Acknowledgments

We thank Stephen Ordway and Gary Howard for editorial review of the manuscript and Chris Barker from the Gladstone Genomics Core. In loving memory of Karen Vranizan and Milo Salomonis.

Author Contributions

Conceived and designed the experiments: NS MM BRC. Performed the experiments: NS BN LT. Analyzed the data: NS KV. Contributed reagents/materials/analysis tools: NS BN ARP KH AK BRC. Wrote the paper: NS. Was the lead investigator: MM.

References

1. Ivanova N, Dobrin R, Lu R, Kostenko I, Levorse J, et al. (2006) Dissecting self-renewal in stem cells with RNA interference. Nature 442: 533–538.
2. Mitschele E (1991) [Diagonal incision in capsulotomy for extracapsular cataract extraction]. Klin Monatbl Augenheilk 199: 406–408.
3. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, et al. (2005) Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122: 947–956.
4. Lob VH, Wu Q, Chew JL, Vega VB, Zhang W, et al. (2006) The Orel and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet 38: 431–440.
5. Lee C, Wang Q (2005) Bioinformatics analysis of alternative splicing. Brief Bioinform 6: 23–33.
6. Cooper TA (2005) Alternative splicing regulation impacts heart development. Cell 120: 1–2.
7. Xu X, Yang D, Ding JH, Wang W, Chu PH, et al. (2005) ASF/SF2-regulated CaMKII delta alternative splicing temporally reprograms excitation-contraction coupling in cardiac muscle. Cell 120: 59–72.
8. Hammes A, Gun S, Lunch G, Leheste JR, Landrock D, et al. (2001) Two splice variants of the Wilms' tumor 1 gene have distinct functions during sex determination and nephron formation. Cell 106: 319–329.
9. Burgess RW, Nguyen QT, Son YJ, Letchman JW, Sanes JR (1999) Alternatively spliced isoforms of nerve- and muscle-derived agrin: their roles at the neuromuscular junction. Neuron 23: 33–44.
10. Yeo GW, Xu X, Liang TY, Muestr AR, Carson CT, et al. (2007) Alternative splicing events identified in human embryonic stem cells and neural progenitors. Proc Natl Acad Sci U S A 104: 1951–1956.
11. Kita-Matsuho H, Barcowa M, Prigoshina N, Salomonis N, Wei K, et al. (2009) Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes. PLoS ONE 4: e5046.
12. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207–210.
13. http://www.affymetrix.com/support/technical/sample_data/exon_array_data.affx
14. Hubbard TJ, Aken BL, Ayliffe S, Ballester B, Beal K, et al. (2009) Ensembl 2009. Nucleic Acids Res 37: D690–D697.
15. Kuhn RM, Karolchik D, Zweig AS, Wang T, Smith KE, et al. (2009) The UCSC Genome Browser Database: update 2009. Nucleic Acids Res 37: D755–D761.
16. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
17. http://www.affymetrix.com/support/developer/powertools/index.affx
18. http://www.affymetrix.com/support/technical/whitepapers/exon_alt_transcript_analysis_whitepaper.pdf
19. Dudoit S, Gentleman RC, Quackenbush J (2003) Open source software for the analysis of microarray data. Biotechniques Suppl. pp 45–51.
20. Krishnan K, Salomonis N, Guo S (2008) Identification of Sp5 target genes in zebrafish brain development reveals its dual activity in vivo. PLoS ONE 3: e3621.
21. Pico AR, Kelder T, van Iersel MP, Haanpaa K, Cordill BR, et al. (2008) WikiPathways: pathway editing for the people. PLoS Biol 6: e184.
22. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863–14868.
23. Taneri B, Snyder B, Novoradovsky A, Gaasterland T (2004) Alternative splicing of mouse transcription factors affects their DNA-binding domain architecture and its tissue specific. Genome Biol 5: K7.
24. Xu Q, Modrek B, Lee C (2002) Genome-wide detection of tissue-specific alternative splicing in the human transcriptome. Nucleic Acids Res 30: 3754–3766.
25. Sanfilippo R, Nelson JR, Sarma A, Sharp PA, Burge CB (2008) Proliferating cells express mRNAs with shortened 3′ untranslated regions and fewer microRNA target sites. Science 320: 1643–1647.
26. Grskovic M, Chavdaropil C, Gaspar-Maia A, Li H, Ramalho-Santos M (2007) Systematic identification of cis-regulatory sequences active in mouse and embryonic stem cells. PLoS Genet 3: e143.
27. Misquitta GM, Mocanu J, Nie L, Greer AK (2002) Sarcoplasmic reticulum Ca(2+) pump mRNA stability in cardiac and smooth muscle: role of the 3′-untranslated region. Am J Physiol Cell Physiol 283: C560–C568.
28. Periasamy M, Kalayanaraman A (2007) SERCA pump isoforms: their role in calcium transport and disease. Muscle Nerve 35: 430–442.
29. Goeman DJ, Andersen LB, Cox J, Swaroop M, Collins FS (1993) An alternatively-spliced mRNA in the carboxy terminus of the neurofibromatosis type 1 (NF1) gene is expressed in muscle. Hum Mol Genet 2: 899–902.
30. Imamura K, Noguchi T, Tanaka T (1986) Regulation of isozyme patterns of pyruvate kinase in normal and neoplastic tissues. In: Staal GEJ, van Velden CWM, eds. Markers of Human Neuroectodermal Tumors. Boca Raton, FL: CRC Press. pp 191–222.
31. Magendzo K, Shirvan A, Cultraro C, Srivastava M, Pollard HB, et al. (1991) Alternative splicing of human synxin mRNA in brain, cardiac, and skeletal muscle alters the unique N-terminal domain. J Biol Chem 266: 3222–3232.
32. Dombraucks JD, Santarriero BD, Mesecar AD (2005) Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 44: 9417–9429.
33. Witt S, Ziesenias A, Fock U, Jochumsch BM, Illenberger S (2004) Comparative biochemical analysis suggests that vinculin and metavinculin cooperate in muscular adhesion sites. J Biol Chem 279: 31533–31543.
34. Ivey KN, Muth A, Arnold J, King FW, Yeh RF, et al. (2008) MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. Cell Stem Cell 2: 219–229.
35. Xing Y, Stolov P, Kapur K, Han A, Jiang H, et al. (2008) MADS: a new and improved method for analysis of differential alternative splicing by exon-tiling microarrays. RNA 14: 1470–1478.
36. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, et al. (2002) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110: 479–488.
37. Makino Y, Kanopka A, Wilson WJ, Tanaka H, Poellinger L (2002) Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-inhibitor locus. J Biol Chem 277: 32403–32408.
38. Fan GC, Yuan Q, Kranias EG (2008) Regulatory roles of junctin in sarcoplasmic reticulum calcium cycling and myocardial function. Trends Cardiovasc Med 18: 1–5.
49. Hong CS, Kwon SJ, Kim do H (2007) Multiple functions of junctin and junctate, two distinct isoforms of aspartyl beta-hydroxylase. Biochem Biophys Res Commun 362: 1-4.
50. de la Monte SM, Tamaki S, Cantarini MC, Ince N, Wiedmann M, et al. (2006) Aspartyl-asparaginyl-beta-hydroxylase regulates hepatocellular carcinoma invasiveness. J Hepatol 44: 971-983.
51. Hayes NV, Scott C, Heerkens E, Ohanian V, Maggs AM, et al. (2000) Identification of a novel C-terminal variant of beta II spectrin: two isoforms of beta II spectrin have distinct intracellular locations and activities. J Cell Sci 113 (Pt 11): 2023-2034.
52. Chen Y, Yu P, Lu D, Tagle DA, Cai T (2001) A novel isoform of beta-spectrin II localizes to cerebellar Purkinje-cell bodies and interacts with neurofibromatosis type 2 gene product schwannomin. J Mol Neurosci 17: 59-70.
53. Raines AJ, Pinder JC (2005) The spectrin-associated cytoskeleton in mammalian heart. Front Biosci 10: 3020-3033.
54. Vitola SJ, Wang A, Sun XH (1996) Substitution of basic amino acids in the basic region stabilizes DNA binding by E12 homodimers. Nucleic Acids Res 24: 1921-1927.
55. Davidsson D, Fourmel M, Veillette A (1994) Oncogenic activation of p21 ras tyrosine protein kinase by mutation of its carboxyl-terminal site of tyrosine phosphorylation, tyrosine 528. J Biol Chem 269: 10956-10963.
56. Caplan S, Hartnell LM, Aguilar RC, Naslavsky N, Bonifacino JS (2001) Human Vam6p promotes lysosome clustering and fusion in vivo. J Cell Biol 154: 109-122.
57. Yan B, Omar FM, Das K, Ng WH, Lim C, et al. (2008) Characterization of Numb expression in astrocytomas. Neuropathology 28: 479-484.
58. Mulherkar N, Prasad KV, Prabhakar BS (2007) MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation. Knockdown enhances TRAIL-induced apoptosis of cancer cells. J Biol Chem 282: 11715-11721.
59. Veerl JM, Bashirullah A, Goddavak DE, Kubu CJ, Jamali M, et al. (1999) Distinct human NUMB isoforms regulate differentiation vs. proliferation in the neuronal lineage. Proc Natl Acad Sci U S A 96: 10472-10476.
60. Toriya M, Tokunaga A, Sawamoto K, Nakao K, Okano H (2006) Distinct functions of human numb isoforms revealed by misexpression in the neural stem cell lineage in the Drosophila larval brain. Dev Neurosci 28: 142-155.
61. Lakshmipathy U, Love B, Goff LA, Jornsten R, Graichen R, et al. (2007) MicroRNA expression pattern of undifferentiated and differentiated human embryonic stem cells. Stem Cells Dev 16: 1003-1016.
62. Garzon R, Pichiari F, Palumbo T, Isolano R, Gimino A, et al. (2006) MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A 103: 5078-5083.
63. Vandenbussche F, Janssens V, De Smedt S, De Rooij D, Geerts S, et al. (2008) Cell-cycle control of microRNA-mediated translation regulation. Cell Cycle 7: 1545-1549.
64. Lee J, Rhe K, Bae GY, Han YM, Kim J (2005) Stimulation of Oct-4 activity by Ewing's sarcoma protein. Stem Cells 23: 738-751.
65. Garzon R, Pichiari F, Palumbo T, Isolano R, Gimino A, et al. (2006) MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A 103: 5078-5083.
66. Purdom E, Simpson KM, Robinson MD, Cowboy JG, Lapuk AV, et al. (2008) FIRMA: a method for detection of alternative splicing from exon array data. Bioinformatics 24: 1707-1714.